

# Driving Transformation. Delivering Growth.

Mendorong Transformasi. Memacu Pertumbuhan.



#### PUBLIC EXPOSE PT Darya-Varia Laboratoria Tbk 6 June 2017

#### **Topics**

- 1. Market Overview
- 2. DVL at Glance
- 3. DVL Business Overview FY 2016
- 4. DVL Performance 1st Q 2017



#### **Market Overview**






## Indonesia Economy Indicators Growth Improvement & Low Inflation

#### **REAL GDP GROWTH**

#### (growth quarterly yoy, percent) 8 6 5 Dec-10 Dec-12 Dec-14 Dec-16 Source: BPS; World Bank staff calculations

#### **INFLATION**




Note: The "Food' category includes both raw and processed food, while "Other items" consist of clothing, health, education, recreation, and sports.

Source: BPS; CEIC; World Bank staff calculations




#### **Indonesia Economy Indicators**

#### Rupiah Strengthening in 2016





## Indonesia Economy Indicators Country With High Consumer Confidence Index





#### **Pharmaceutical Industry Growth**

I- 0/	MAT	4Q16 vs MAT	4Q15	CAGR 5 Y		
In %	TOTAL	MNC	DOMESTIC	TOTAL	MNC	DOMESTIC
TOTAL	7.49	5.14	8.43	7.80	9.83	7.07
ETHICAL	8.13	4.99	9.94	8.59	10.80	7.47
ETHICAL BRANDED	5.92	4.78	6.81	7.77	10.71	5.76
UNBRANDED GENERIC	18.64	24.90	18.50	12.51	19.40	12.37
FREE SALES	6.45	5.74	6.57	6.54	6.39	6.57

Market grew mainly driven by generics, while branded Ethical and OTC product growth are single digit

Source: QuintilesIMS – Report February 2017

Indonesia Quarterly Pharma Market Update Q4 2016

## Sekilas Darya-Varia Darya-Varia at a Glance





#### Menjadi perusahaan terbaik yang menyediakan solusi kesehatan berkualitas di Indonesia

We shall be the best provider of quality health and wellness solutions in Indonesia

Membangun Indonesia yang lebih sehat setiap orang di setiap waktu dengan produk dan pelayanan yang unggul, bekerja sama dalam sebuah keluarga "BERSATU"

We build a healthier Indonesia one person at a time with market leading products and services, working together as one "BERSATU" family





1976

A new partner in health.



1994

Taking further step.





2012

Breaking new heights. \_\_\_\_\_\_



2016

Committed to a healthier Indonesia.



**FOR A HEALTHIER INDONESIA** 



#### **BISNIS UTAMA**

#### MAIN BUSINESS STREAMS



Bisnis Obat Resep
Prescription Business



Bisnis Consumer Health
Consumer Health Business



Bisnis Export & Toll

Manufacturing

Export & Toll Manufacturing Business



#### **Production Facilities**





Citeureup, Bogor (Sterile & Solid)

Gunung Putri, Bogor (Soft Capsule, Liquid, Cosmetic)









#### **New Product Launch - PRESCRIPTION**





DEXTOFEN®
Dexketoprofen trometamol
25 mg/mL

Linepar #2 m.

Darge-Vérile

Constitution

Sodium

**Dextofen** 



Dipitenz



Dexketoprofen



**Burnazin Plus** 



**IAL System** 

#### **Medical Science Center**



- Journal for doctors
- Webinar
- 9 MSCs in 6 big cities
- RSUD dr. Soetomo, Surabaya
- RS Hasan Sadikin, Bandung
- RS Adam Malik, Medan
- Rs Wahidin S, Makassar
- RS M. Hoesni, Palembang
- RSPAD Gatot Soebroto, Jakarta
- RS Kanker Dharmais, Jakarta
- RS Fatmawati, Jakarta
- RS Harapan Kita, Jakarta











#### **New Product Launch - CONSUMER HEALTH**













### **Communication Program**Consumer Health













#### **DVL Business Overview FY 2016**



#### **DVL Performance FY 2016**

	Sales (BIDR)	Growth
Bisnis Obat Resep (Prescription Business)	479	11%
Bisnis Consumer Health (Consumer Health Business)	653	12%
Bisnis Ekspor & Toll Manufacturing (Export & Toll Manufacturing Business)	319	9%
Total Net Sales	1,451	11%



#### LAPORAN LABA RUGI STATEMENT OF PROFIT OR LOSS FY 2016

Uraian (dalam miliar Rupiah)	2016	2015	% Pertumbuhan % Growth	Description (in billion Rupiah)
Laba Bruto	801	678	18%	Gross Income
Laba Usaha	204	127	61%	Operating Income
Laba Bersih	152	108	41%	Net Income
Marjin Laba Bersih	10%	8%		Net Income Margin
Laba bersih per saham (Rupiah penuh)	136	97	40%	Net Income per Share (full rupiah)



## LAPORAN POSISI KEUANGAN STATEMENT OF FINANCIAL POSITION FY 2016

Uraian (dalam miliar Rupiah)	2016	2015	Increase/ (Decrease)	Description (in billion Rupiah)
Jumlah Aset	1,531	1,376	11%	Total Assets
Aset Lancar	1,069	1,044	2%	Current Assets
Jumlah Liabilitas	452	403	12%	Total Liabilities
Liabilitas Jangka Pendek	374	296	26%	Current Liabilities
Jumlah Ekuitas	1,080	974	11%	Equity




## LAPORAN ARUS KAS STATEMENT OF CASH FLOWS FY 2016

Uraian (dalam miliar Rupiah)	2016	2015	Increase/ Decrease	Description (in billion Rupiah)
Arus kas dari aktivitas operasional	187	214	(12%)	Cash flows from operations
Arus kas untuk aktivitas investasi	(197)	(39)	405%	Cash flows used in investing activities
Arus kas untuk aktivitas pendanaan	(39)	(78)	(50%)	Cash flows used in financing activities



# PEMBAYARAN DIVIDEN DIVIDEND PAYMENT FY 2013-2016



Financial Year



#### **DVL Performance 1st Q 2017**



#### **DVL Performance Q1 2017**

	Sales (BIDR)	Growth
Bisnis Obat Resep (Prescription Business)	156	14%
Bisnis Consumer Health (Consumer Health Business)	176	6%
Bisnis Ekspor & Toll Manufacturing (Export & Toll Manufacturing Business)	66	(14%)
Total Net Sales	398	5%



#### LAPORAN LABA RUGI STATEMENT OF PROFIT OR LOSS Q1 2017

Uraian (dalam miliar Rupiah)	Q1 2017	Q1 2016	% Pertumbuhan % Growth	Description (in billion Rupiah)
Laba Bruto	248	207	20%	Gross Income
Laba Usaha	106	70	51%	Operating Income
Laba Bersih	84	57	47%	Net Income
Marjin Laba Bersih	21%	15%		Net Income Margin
Laba bersih per saham (Rupiah penuh)	75	51	47%	Net Income per Share (full rupiah)



## LAPORAN POSISI KEUANGAN STATEMENT OF FINANCIAL POSITION Q1 2017

Uraian (dalam miliar Rupiah)	Q1 2017	Q4 2016	Increase/ (Decrease)	Description (in billion Rupiah)
Jumlah Aset	1,721	1,531	12%	Total Assets
Aset Lancar	1,266	1,069	18%	Current Assets
Jumlah Liabilitas	559	452	24%	Total Liabilities
Liabilitas Jangka Pendek	477	374	28%	Current Liabilities
Jumlah Ekuitas	1,161	1,080	8%	Equity



# LAPORAN ARUS KAS STATEMENT OF CASH FLOWS Q1 2017

Uraian (dalam miliar Rupiah)	Q1 2017	Q1 2016	Increase/ Decrease	Description (in billion Rupiah)
Arus kas dari aktivitas operasional	71	52	38%	Cash flows from operations
Arus kas untuk aktivitas investasi	(6)	(8)	24%	Cash flows used in investing activities
Arus kas untuk aktivitas pendanaan	-	_	_	Cash flows used in financing activities





# FOR A HEALTHIER INDONESIA